Surprising Findings in Prospective Budesonide-Eosinophilic Esophagitis Study

A recent study (ES Dellon et al Clin Gastroenterol Hepatol 2019; 17: 666-73) prospectively followed patients in a 24 week open-label extension of a randomized, double-blind, placebo-controlled trial of budesonide oral suspension (BOS) for eosinophilic esophagitis (EoE). The authors defined histologic response as ≤6 eos/hpf. During the extension, the dosage of BOS was reduced from 2 mg twice daily to 2 mg once a day.

Key findings:

  • No new safety signals. One patient in placebo/BOS arm (n=37) developed oral candidiasis and one patient in the BOS/BOS arm (n=45) did as well. In addition, four patients in placebo/BOS developed esophageal candidiasis. No clinically relevant changes in morning serum cortisol levels were identified.
  • Histologic response was observed in 49% (16/33) in placebo/BOS arm and 23% (9/39) of BOS/BOS arm. 58% of placebo/BOS and 28% of BOS/BOS patients had ≤15 eos/hpf.
  • Mean peak eosinophil count decreased in placebo/BOS arm from 119 to 29 and increased in BOS/BOS arm from 38 to 72.
  • Overall, only 42% of patients who responded to BOS during double-blind 12 week study maintained a histologic response.

While this study shows that BOS is effective for many patients with EoE, it also shows that many lose a response.  In addition, most patients who “did not respond to treatment during the double-blind phase did not gain a histologic or endoscopic response with longer-term treatment.”  Only 1 of 26 patients (4%) gained a response. This has several important implications:

  • Some patients may develop corticosteroid resistance
  • In patients who respond to induction, it may be prudent to continue with the same induction dose rather than reducing the dosage
  • In patients who do not respond to induction, further treatment is not beneficial

My take: Though the response to BOS was not very high in this study, the population studied was highly symptomatic and had histologically-severe EoE.  Thus, in a more typical population of patients with EoE, the response rate is likely to be more favorable. Also, many patients will not maintain a response to BOS at a lowered dose.

Related blog posts:

Boqureia Market, Barcelona


Disclaimer: These blog posts are for educational purposes only. Specific dosing of medications/diets (along with potential adverse effects) should be confirmed by prescribing physician/nutritionist.  This content is not a substitute for medical advice, diagnosis or treatment provided by a qualified healthcare provider. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a condition.

8 thoughts on “Surprising Findings in Prospective Budesonide-Eosinophilic Esophagitis Study

  1. Pingback: Orodispensable Budesonide Tablets for Eosinophilic Esophagitis | gutsandgrowth

  2. Pingback: Head-to-Head: Budesonide vs Fluticasone for Eosinophilic Esophagitis | gutsandgrowth

  3. Pingback: EoP –Biomarker or Balderdash? | gutsandgrowth

  4. Pingback: Grading Treatment Response in Eosinophilic Esophagitis | gutsandgrowth

  5. Pingback: New 2020 Eosinophilic Esophagitis Guidelines | gutsandgrowth

  6. Pingback: Phase 3 Trial of Budesonide for Eosinophilic Esophagitis & COVID-19 Deaths in U.S. | gutsandgrowth

  7. Pingback: Lingering Histologic Changes with Eosinophilic Esophagitis in Remission, Plus One | gutsandgrowth

  8. Pingback: Budesonide for Maintaining EoE Remission | gutsandgrowth

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.